6/10/2023

Janusmed kön och genus

Janusmed kön och genus – rilpivirin

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
A A
A A

Rilpivirin

Rilpivirin

Klass: A

Visa all info

Skriv ut

Kontakta oss

Produkter

EDURANT, Eviplera, Juluca, Odefsey, REKAMBYS

EDURANT, Eviplera, Juluca, Odefsey, REKAMBYS
ATC-koder

J05AG05, J05AR08, J05AR19, J05AR21

J05AG05, J05AR08, J05AR19, J05AR21
Substanser

rilpivirin, rilpivirinhydroklorid

rilpivirin, rilpivirinhydroklorid
Sammanfattning

Inga skillnader mellan män och kvinnor i farmakokinetik eller effekt av rilpivirin har presenterats. Illamående har rapporterats oftare som biverkan hos kvinnor och mardrömmar oftare hos män.

Inga skillnader mellan män och kvinnor i farmakokinetik eller effekt av rilpivirin har presenterats. Illamående har rapporterats oftare som biverkan hos kvinnor och mardrömmar oftare hos män.
Background

Antiretrovirals for treatment of HIV are always given as a combination of at least three medicines. Cobicistat is used to boost the effect of other antiretroviral drugs. As studies on HIV patients always include patients receiving combination therapy it is difficult to know which of the studied medicines that cause changes in effect and/or adverse events.

Pharmacokinetics and dosing
The manufacturer reports no clinically relevant differences between men and women in the pharmacokinetics of rilpivirine and suggests no differences in dosing [1].

Effects
Both men and women have been included in the randomized trials [1]. In a randomized study in HIV infected adults (1040 men, 328 women) treated with rilpivirine or efavirenz plus tenofovir/emtricitabine, zidovudine/lamivudine or abacavir/lamivudine, no difference between men and women was found in achieving virological suppression response [2].

Adverse effects
In a randomized study in HIV infected adults (1040 men, 328 women) treated with rilpivirine or efavirenz plus tenofovir/emtricitabine or, zidovudine/lamivudine or abacavir/la......

Visa hela bakgrundstexten

Antiretrovirals for treatment of HIV are always given as a combination of at least three medicines. Cobicistat is used to boost the effect of other antiretroviral drugs. As studies on HIV patients always include patients receiving combination therapy it is difficult to know which of the studied medicines that cause changes in effect and/or adverse events. # Pharmacokinetics and dosing The manufacturer reports no clinically relevant differences between men and women in the pharmacokinetics of rilpivirine and suggests no differences in dosing [1]. # Effects Both men and women have been included in the randomized trials [1]. In a randomized study in HIV infected adults (1040 men, 328 women) treated with rilpivirine or efavirenz plus tenofovir/emtricitabine, zidovudine/lamivudine or abacavir/lamivudine, no difference between men and women was found in achieving virological suppression response [2]. # Adverse effects In a randomized study in HIV infected adults (1040 men, 328 women) treated with rilpivirine or efavirenz plus tenofovir/emtricitabine or, zidovudine/lamivudine or abacavir/lamivudine nausea was more common in women in both treatment groups while abnormal dreams/nightmares were more frequent in men [2]. # Reproductive health issues Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).
Försäljning på recept

Visa hela försäljning på recept

Fler män än kvinnor hämtade ut läkemedel innehållande rilpivirin (ATC-kod J05AG05) på recept i Sverige år 2017, totalt 82 män och 31 kvinnor [3].
Referenser

Visa referenser

  1. EDURANT (rilpivirine). Summary of Product Characteristics. European Medicines Agency (EMA); 2018.

  2. Hodder S, Arasteh K, De Wet J, Gathe J, Gold J, Kumar P et al. Effect of gender and race on the week 48 findings in treatment-naïve, HIV-1-infected patients enrolled in the randomized, phase III trials ECHO and THRIVE. HIV Med. 2012;13(7):406-15.

  3. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2017 [cited 2018-07-24.]

  1. EDURANT (rilpivirine). Summary of Product Characteristics. European Medicines Agency (EMA); 2018.
  2. Hodder S, Arasteh K, De Wet J, Gathe J, Gold J, Kumar P et al. Effect of gender and race on the week 48 findings in treatment-naïve, HIV-1-infected patients enrolled in the randomized, phase III trials ECHO and THRIVE. HIV Med. 2012;13(7):406-15.
  3. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2017 [cited 2018-07-24.]
Uppdaterat

Litteratursökningsdatum 7/18/2018

Litteratursökningsdatum 7/18/2018